Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Infantile Spasm (West Syndrome) Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Infantile Spasm (West Syndrome) Overview | 7 | 1 |
| Infantile Spasm (West Syndrome) Therapeutics under Development by Companies | 8 | 1 |
| Infantile Spasm (West Syndrome) Pipeline Products Glance | 9 | 2 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Infantile Spasm (West Syndrome) Products under Development by Companies | 11 | 1 |
| Infantile Spasm (West Syndrome) Companies Involved in Therapeutics Development | 12 | 5 |
| Anavex Life Sciences Corp. | 12 | 1 |
| Catalyst Pharmaceuticals, Inc. | 13 | 1 |
| INSYS Therapeutics, Inc. | 14 | 1 |
| Novartis AG | 15 | 1 |
| Retrophin Inc. | 16 | 1 |
| Infantile Spasm (West Syndrome) Therapeutics Assessment | 17 | 9 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Target | 18 | 2 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Drug Profiles | 26 | 10 |
| ANAVEX-273 - Drug Profile | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 2 |
| AVL-5189 - Drug Profile | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| cannabidiol - Drug Profile | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| cosyntropin - Drug Profile | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| cosyntropin ER - Drug Profile | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| CPP-115 - Drug Profile | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 3 |
| Infantile Spasm (West Syndrome) Recent Pipeline Updates | 36 | 11 |
| Infantile Spasm (West Syndrome) - Dormant Projects | 47 | 1 |
| Infantile Spasm (West Syndrome) Product Development Milestones | 48 | 6 |
| Featured News &Press Releases | 48 | 1 |
| May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms | 48 | 1 |
| Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD | 48 | 1 |
| Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115 | 49 | 1 |
| Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms | 49 | 1 |
| Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 | 50 | 1 |
| Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115 | 50 | 1 |
| Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia | 51 | 1 |
| Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome | 52 | 1 |
| Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference | 52 | 1 |
| Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |